Congruently, there was a significantly longer PFS and OS benefit with pembrolizumab compared with standard platinum-based chemotherapy in the KEYNOTE-O24 trial that enrolled only NSCLC patients with ≥50% PD-L1 tumour proportion score [14]. Here, CD274 is linked to neoplasm.